ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and children aged 6 years and ...

A Thai woman condemned a private hospital in the central province of Samut Sakhon after treatment for nasal polyps left her boyfriend blind.

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...

Women aged 60 years or older had a 32% higher likelihood of CRSsNP diagnosis (OR 1.32). Women had a 37% lower chance of being ...

ENT and (ENTA), the nation’s preeminent otolaryngology, allergy, and audiology practice, proudly announces that board-certified otolaryngologist Michael Katz, MD, ...

Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...

AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...